CRISPR Therapeutics AG (CRSP)
54.01
+0.28
(+0.52%)
USD |
NASDAQ |
Apr 26, 12:34
CRISPR Therapeutics Research and Development Expense (Quarterly): 95.14M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 95.14M |
| September 30, 2023 | 90.70M |
| June 30, 2023 | 101.56M |
| March 31, 2023 | 99.94M |
| December 31, 2022 | 103.56M |
| September 30, 2022 | 116.62M |
| June 30, 2022 | 123.22M |
| March 31, 2022 | 118.24M |
| December 31, 2021 | 103.10M |
| September 30, 2021 | 83.50M |
| June 30, 2021 | 82.33M |
| March 31, 2021 | 70.62M |
| December 31, 2020 | 82.36M |
| September 30, 2020 | 71.01M |
| June 30, 2020 | 59.38M |
| March 31, 2020 | 54.19M |
| December 31, 2019 | 48.76M |
| Date | Value |
|---|---|
| September 30, 2019 | 57.25M |
| June 30, 2019 | 39.53M |
| March 31, 2019 | 33.82M |
| December 31, 2018 | 28.80M |
| September 30, 2018 | 39.82M |
| June 30, 2018 | 25.63M |
| March 31, 2018 | 19.52M |
| December 31, 2017 | 20.03M |
| September 30, 2017 | 17.84M |
| June 30, 2017 | 17.12M |
| March 31, 2017 | 14.80M |
| December 31, 2016 | 15.57M |
| September 30, 2016 | 12.05M |
| June 30, 2016 | 8.602M |
| March 31, 2016 | 6.012M |
| December 31, 2015 | 6.174M |
| September 30, 2015 | 3.749M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
39.53M
Minimum
Jun 2019
123.22M
Maximum
Jun 2022
84.26M
Average
83.50M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 824.60M |
| Intellia Therapeutics Inc | 108.98M |
| Novartis AG | 2.421B |
| Verve Therapeutics Inc | 46.81M |
| AC Immune SA | 16.52M |